Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mayne Pharma Group ( (AU:MYX) ) just unveiled an announcement.
Mayne Pharma Group has released an investor presentation detailing its third-quarter fiscal 2026 results, following their initial announcement to the market on 29 April 2026. The presentation, authorised by the board chair, is intended to give investors and stakeholders a structured overview of the company’s recent financial and operational performance, reinforcing its ongoing communication with the market through regular updates and digital investor engagement channels.
The most recent analyst rating on (AU:MYX) stock is a Buy with a A$6.10 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma Group Limited is an ASX-listed specialty pharmaceutical company focused on commercialising novel medicines that are safer, better and more accessible for patients. It is a leader in dermatology and women’s health in the United States and also provides contract development and manufacturing services globally, underpinned by a 40-year track record in oral drug delivery innovation.
Average Trading Volume: 477,939
Technical Sentiment Signal: Sell
Current Market Cap: A$228.3M
Find detailed analytics on MYX stock on TipRanks’ Stock Analysis page.